Basilea Pharmaceutica (BPMUF)
(Delayed Data from OTC)
$51.26 USD
0.00 (0.00%)
Updated Aug 19, 2024 10:04 AM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Balance Sheet
Fiscal Year End for Basilea Pharmaceutica AG falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 72 | 91 | 164 | 178 | 132 |
Receivables | 65 | 65 | 71 | 35 | 28 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 29 | 25 | 25 | 23 | 19 |
Other Current Assets | 4 | 3 | 4 | 3 | 7 |
Total Current Assets | 169 | 184 | 264 | 238 | 186 |
Net Property & Equipment | 4 | 4 | 2 | 3 | 5 |
Investments & Advances | 0 | 0 | 0 | 0 | 30 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 1 | 1 | 1 | 1 | 0 |
Deposits & Other Assets | 0 | 24 | 3 | 0 | 1 |
Total Assets | 193 | 231 | 271 | 245 | 223 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 0 | 12 | 14 | 7 |
Current Portion Long-Term Debt | 17 | 39 | 135 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 26 | 36 | 42 | 35 | 36 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 1 | 1 | 3 | 33 |
Total Current Liabilities | 53 | 78 | 191 | 54 | 76 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 11 | 11 | 13 | 14 | 17 |
Convertible Debt | 106 | 100 | 103 | 256 | 199 |
Long-Term Debt | 0 | 38 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 17 | 9 | 27 | 30 | 25 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 204 | 253 | 335 | 354 | 316 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 15 | 14 | 14 | 13 | 12 |
Capital Surplus | 1,161 | 1,087 | 1,127 | 1,048 | 933 |
Retained Earnings | -1,115 | -1,060 | -1,120 | -1,084 | -1,008 |
Other Equity | -11 | -4 | -24 | -29 | -25 |
Treasury Stock | 60 | 59 | 62 | 56 | 6 |
Total Shareholder's Equity | -11 | -22 | -64 | -109 | -94 |
Total Liabilities & Shareholder's Equity | 193 | 231 | 271 | 245 | 223 |
Total Common Equity | -11 | -22 | -64 | -109 | -94 |
Shares Outstanding | 11.80 | 11.80 | 10.70 | 10.70 | 11.80 |
Book Value Per Share | -0.94 | -1.84 | -5.99 | -10.17 | -7.93 |
Fiscal Year End for Basilea Pharmaceutica AG falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | 72 | -99,999 | -99,898 |
Receivables | NA | NA | 65 | NA | 72 |
Notes Receivable | NA | NA | 0 | NA | NA |
Inventories | NA | NA | 29 | NA | 29 |
Other Current Assets | NA | NA | 4 | NA | 5 |
Total Current Assets | NA | NA | 169 | NA | 207 |
Net Property & Equipment | NA | NA | 4 | NA | 4 |
Investments & Advances | NA | NA | 0 | NA | NA |
Other Non-Current Assets | NA | NA | 0 | NA | NA |
Deferred Charges | NA | NA | 0 | NA | NA |
Intangibles | NA | NA | 1 | NA | 1 |
Deposits & Other Assets | NA | NA | 0 | NA | 25 |
Total Assets | NA | NA | 193 | NA | 256 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | 0 | NA | NA |
Accounts Payable | NA | NA | 7 | NA | 4 |
Current Portion Long-Term Debt | NA | NA | 17 | NA | 42 |
Current Portion Capital Leases | NA | NA | 0 | NA | NA |
Accrued Expenses | NA | NA | 26 | NA | 25 |
Income Taxes Payable | NA | NA | 0 | NA | NA |
Other Current Liabilities | NA | NA | 1 | NA | 1 |
Total Current Liabilities | NA | NA | 53 | NA | 75 |
Mortgages | NA | NA | 0 | NA | NA |
Deferred Taxes/Income | NA | NA | 11 | NA | 11 |
Convertible Debt | NA | NA | 106 | NA | 106 |
Long-Term Debt | NA | NA | 0 | NA | 20 |
Non-Current Capital Leases | NA | NA | 0 | NA | NA |
Other Non-Current Liabilities | NA | 17 | NA | 9 | |
Minority Interest (Liabilities) | NA | NA | 0 | NA | NA |
Total Liabilities | NA | NA | 204 | NA | 239 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | 0 | NA | NA |
Common Stock (Par) | NA | NA | 15 | NA | 15 |
Capital Surplus | NA | NA | 1,161 | NA | 1,157 |
Retained Earnings | NA | NA | -1,115 | NA | -1,090 |
Other Equity | NA | NA | -11 | NA | -4 |
Treasury Stock | NA | NA | 60 | NA | 62 |
Total Shareholder's Equity | NA | NA | -11 | NA | 17 |
Total Liabilities & Shareholder's Equity | NA | NA | 193 | NA | 256 |
Total Common Equity | 0 | 0 | -11 | 0 | 100,016 |
Shares Outstanding | 11.80 | 11.80 | 11.80 | 11.80 | 11.80 |
Book Value Per Share | 0.00 | 0.00 | -0.94 | 0.00 | 8,475.90 |